Par/Three Rivers Ribavirin ANDA Is "Approvable"

Launch of the Rebetol generic is "on the near-term horizon," Par CEO Tarriff says. Approval is contingent on resolution of labeling issues.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet